CytomX Therapeutics (CTMX) PT Lowered to $8 at BTIG
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- Goldman data shows hedge funds cut leverage at fastest pace since March
Tweet
Share
E-mailGet Alerts CTMX Hot Sheet
Price: $2.23 --0%
Rating Summary:
14 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 15 | New: 12
Rating Summary:
14 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 15 | New: 12
Join SI Premium – FREE
BTIG analyst Kaveri Pohlman lowered the price target on CytomX Therapeutics (NASDAQ: CTMX) to $8.00 (from $16.00) while maintaining a Buy rating.
You May Also Be Interested In
- CytomX Therapeutics to Present at Upcoming November Investor Conferences
- EVgo, Inc. (EVGO) PT Lowered to $2 at Cantor Fitzgerald
- Assembly Biosciences (ASMB) PT Lowered to $48 at UBS
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
